Biogen financials
$227.07−0.71%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B |
| Gross profit | $7.49B | $7.37B | $7.30B | $7.90B | $8.87B | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B |
| Gross margin | 75.7% | 76.1% | 74.2% | 77.6% | 80.8% | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% |
| Operating income | $1.86B | $2.16B | $1.61B | $2.77B | $2.84B | $4.46B | $7.04B | $5.89B | $5.46B | $5.17B |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B |
| Net margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% |
| Diluted EPS | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 |
| EBITDA | $2.74B | $2.86B | $2.33B | $3.42B | $3.28B | $4.83B | $7.50B | $6.54B | $6.60B | $6.34B |
| Operating cash flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.62B | $4.23B | $7.08B | $6.19B | $4.55B | $4.59B |
| Free cash flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.36B | $3.81B | $6.26B | $3.92B | $2.48B | $2.77B |
| Diluted shares | 147.1M | 145.9M | 145.6M | 146.0M | 149.6M | 161.3M | 187.4M | 205.3M | 213.0M | 218.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $3.01B | $2.38B | $1.05B | $3.42B | $2.26B | $1.33B |
| Short-term investments | $807.2M | $0.00 | $0.00 | $1.47B | $1.54B | $1.28B |
| Total debt | $6.29B | $6.30B | $6.94B | $6.28B | $7.27B | $7.43B |
| Total assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B |
| Total liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B | $13.93B |
| Shareholders' equity | $18.26B | $16.72B | $14.80B | $13.39B | $10.96B | $10.69B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology